---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-016852"
form_type: "8-K"
ticker: "MBIO"
cik: "0001680048"
company_name: "MUSTANG BIO, INC."
filed_at: "2023-10-26T23:59:59+00:00"
generated_at: "2026-06-09T08:38:26.132744+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FDA accepts IND for Mustang Bio's MB-109 combo therapy for recurrent glioblastoma

## Summary
- IND accepted within 30 days of submission for MB-109 (MB-101 CAR-T + MB-108 oncolytic virus).
- Phase 1 trial to start 2024; will test safety, tolerability, efficacy in recurrent GBM and high-grade astrocytoma.
- Prior MB-101 alone saw complete responses lasting 7.5 and 31+ months in patients with hot tumors.
- Study to enroll at City of Hope and University of Alabama at Birmingham.
- Median overall survival for recurrent GBM is 6 months; combo aims to improve outcomes.

## SEC filing metadata
- accession: 0001558370-23-016852
- form_type: 8-K
- ticker: MBIO
- cik: 0001680048
- company_name: MUSTANG BIO, INC.
- filed_at: 2023-10-26T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680048/000155837023016852/0001558370-23-016852-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680048/000155837023016852/tmb-20231026x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-016852
- JSON: https://secwatch.observer/filing/0001558370-23-016852.json
- Plain text: https://secwatch.observer/filing/0001558370-23-016852.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.